Literature DB >> 12897403

The incorporation and metabolism of amyloid-beta into chylomicron-like lipid emulsions.

Anthony P James1, Sebely Pal, Hanni C Gennat, Donna F Vine, John C L Mamo.   

Abstract

The aggregation and deposition of amyloid-beta (Abeta) in the brain is thought to be an early event in the pathology of Alzheimer's disease (AD). Many studies have reported the association of Abeta with lipoproteins from plasma suggesting an involvement of lipoprotein particles in Abeta transport. Chylomicron-like lipid emulsions, resembling chylomicrons in composition, size and metabolism were prepared in the presence of [125I]Abeta1-40. Abeta was found to associate significantly with these lipid emulsions during their preparation. The chylomicron-like emulsions containing Abeta were then injected into a lateral ear vein of conscious rabbits and blood sampled at regular intervals up to 30 mins. It was observed that there was no difference in the plasma clearance of [125I]Abeta and that of the 3H-cholesteryl ester, a marker of the emulsion particles, demonstrating that Abeta remains associated with these particles throughout both their lipolysis and tissue uptake. Our results show that Abeta can be metabolised in association with triglyceride rich lipoproteins (TRLs). In addition we report the presence of specific markers of TRLs of hepatic and intestinal origin in human CSF thus suggesting a potential means of cerebral Abeta delivery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12897403     DOI: 10.3233/jad-2003-5302

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  8 in total

1.  Amyloid-beta colocalizes with apolipoprotein B in absorptive cells of the small intestine.

Authors:  Susan Galloway; Ryusuke Takechi; Menuka M S Pallebage-Gamarallage; Satvinder S Dhaliwal; John C L Mamo
Journal:  Lipids Health Dis       Date:  2009-10-22       Impact factor: 3.876

2.  A diet enriched in docosahexanoic Acid exacerbates brain parenchymal extravasation of apo B lipoproteins induced by chronic ingestion of saturated fats.

Authors:  Menuka M Pallebage-Gamarallage; Virginie Lam; Ryusuke Takechi; Susan Galloway; John C L Mamo
Journal:  Int J Vasc Med       Date:  2011-11-10

3.  Synergistic effects of high fat feeding and apolipoprotein E deletion on enterocytic amyloid-beta abundance.

Authors:  Susan Galloway; Menuka M S Pallebage-Gamarallage; Ryusuke Takechi; Le Jian; Russell D Johnsen; Satvinder S Dhaliwal; John C L Mamo
Journal:  Lipids Health Dis       Date:  2008-04-22       Impact factor: 3.876

4.  Amyloid precursor protein mediated changes in intestinal epithelial phenotype in vitro.

Authors:  Kendra L Puig; Gunjan D Manocha; Colin K Combs
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

5.  Amyloid precursor protein modulates macrophage phenotype and diet-dependent weight gain.

Authors:  Kendra L Puig; Stephen A Brose; Xudong Zhou; Mary A Sens; Gerald F Combs; Michael D Jensen; Mikhail Y Golovko; Colin K Combs
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

6.  Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers.

Authors:  Megan M Bernath; Sudeepa Bhattacharyya; Kwangsik Nho; Dinesh Kumar Barupal; Oliver Fiehn; Rebecca Baillie; Shannon L Risacher; Matthias Arnold; Tanner Jacobson; John Q Trojanowski; Leslie M Shaw; Michael W Weiner; P Murali Doraiswamy; Rima Kaddurah-Daouk; Andrew J Saykin
Journal:  Neurology       Date:  2020-05-01       Impact factor: 11.800

7.  The differential effects of fatty acids on enterocytic abundance of amyloid-beta.

Authors:  Susan Galloway; Ryusuke Takechi; Michael Nesbit; Menuka M Pallebage-Gamarallage; Virginie Lam; John C L Mamo
Journal:  Lipids Health Dis       Date:  2019-12-03       Impact factor: 3.876

Review 8.  The Microbiota-Gut-Brain Axis and Alzheimer Disease. From Dysbiosis to Neurodegeneration: Focus on the Central Nervous System Glial Cells.

Authors:  Maria Grazia Giovannini; Daniele Lana; Chiara Traini; Maria Giuliana Vannucchi
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.